menu
    • menu
    [{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HemaXellerate","moa":"Undisclosed","graph1":"Hematology","graph2":"IND Enabling","graph3":"Regen BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regen BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Regen BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Disc medicine","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"MWTX-001","moa":"Undisclosed","graph1":"Hematology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Disc medicine","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ Disc medicine"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CT-001","moa":"Factor VII","graph1":"Hematology","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coagulant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP122G","moa":"Factor XI","graph1":"Hematology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP122G","moa":"Factor XI","graph1":"Hematology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Hematology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Hematology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Regen BioPharma

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            Regen BioPharma

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HemaXellerate

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™

                            Details : HemaXellerate is an innovative stem cell-derived therapy, designed to stimulate bone marrow regeneration, it has already received FDA clearance for treating aplastic anemia.

                            Product Name : HemaXellerate

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 19, 2024

                            Lead Product(s) : HemaXellerate

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ainos

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alpha

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Lind Partners

                            Deal Size : $1.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ainos Announces $1.75 Million Follow-On Funding

                            Details : Veldona (interferon alfa) is progressing towards IND applications for human drug candidates and co-development of VOC sensing tech using AI Nose.

                            Product Name : Veldona

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            January 24, 2024

                            Lead Product(s) : Interferon Alpha

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Lind Partners

                            Deal Size : $1.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hoth Therapeutics

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            Hoth Therapeutics

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-KIT

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's ...

                            Details : HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting, which is investigated for the treatment of advance Cancer Patients.

                            Product Name : HT-KIT

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 14, 2023

                            Lead Product(s) : HT-KIT

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hoth Therapeutics

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            Hoth Therapeutics

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-KIT

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatmen...

                            Details : HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting, which is investigated for the treatment of advance systemic mastocytosis.

                            Product Name : HT-KIT

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 09, 2023

                            Lead Product(s) : HT-KIT

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mabwell

                            China arrow
                            WRIB
                            Not Confirmed

                            Mabwell

                            China arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MWTX-001

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Disc medicine

                            Deal Size : $412.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mabwell Announces Exclusive Licensing Agreement with Disc Medicine, Inc. for Innovative Drug Candidates of Hem...

                            Details : Under the terms of the agreement, Disc will obtain exclusive rights to develop and commercialize 9MW3011. MWTx 01 is a recombinant monoclonal antibody targeting a key regulator in the iron homeostasis pathway, developed to treat iron overload disorders.

                            Product Name : MWTX-001

                            Product Type : Antibody

                            Upfront Cash : $10.0 million

                            January 20, 2023

                            Lead Product(s) : MWTX-001

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Disc medicine

                            Deal Size : $412.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Coagulant Therapeutics

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            Coagulant Therapeutics

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-001

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Coagulant Therapeutics Announces Upcoming Oral and Poster Presentations at the 2022 American Society of Hemato...

                            Details : CT-001 is an engineered version of FVIIa that is designed to address the limitations of the recombinant FVIIa, approved for use in Hemophilia A and B patients with inhibitors, congenital FVII deficiency.

                            Product Name : CT-001

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 16, 2022

                            Lead Product(s) : CT-001

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sirnaomics

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            Sirnaomics

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP122G

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Progra...

                            Details : STP122G comprises RNAi triggers targeting Factor XI. Factor XI is a plasma glycoprotein that is primarily synthesized in the liver and is part of the coagulation cascade, playing a role in clot stabilization and expansion.

                            Product Name : STP122G

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 05, 2022

                            Lead Product(s) : STP122G

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sirnaomics

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            Sirnaomics

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP122G

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics Based on its Proprietary GalA...

                            Details : STP122G is in early-stage development as an anticoagulant in settings where antithrombotic therapeutics are needed such as stroke patients and orthopedic surgery patients. STP122G targets Factor XI, a plasma glycoprotein that is primarily synthesized in ...

                            Product Name : STP122G

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            June 21, 2022

                            Lead Product(s) : STP122G

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth